Alexander Langerman

Alexander Langerman

Auto-generated profile, based on publicly available information

Alexander Langerman

Department of Otolaryngology–Head and Neck Surgery Vanderbilt University Medical Center Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TSTanguy Y. Seiwert
Tanguy Y. Seiwert
ZZZhixiang Zuo
Zhixiang Zuo
MKMichaela K. Keck
Michaela K. Keck
AKArun Khattri
Arun Khattri
CPChandra S. Pedamallu
Chandra S. Pedamallu
PHPeter S. Hammerman
Peter S. Hammerman
Purpose: The genetic differences between human papilloma virus (HPV)–positive and –negative head and neck squamous cell carcinomas (HNSCC) remain largely unknown. To identify differential biology and novel therapeutic targets for both entities, we determined mutations and copy-number aberrations in a large cohort of locoregionally advanced HNSCC. Experimental Design: We performed massively parallel sequencing of 617 cancer-associated genes in 120 matched tumor/normal samples (42.5% HPV-positive). Mutations and copy-number aberrations were determined and results validated with a secondary method. Results: The overall mutational burden in HPV-negative and HPV-positive HNSCC was similar with an average of 15.2 versus 14.4 somatic exonic mutations in the targeted cancer-associated genes. HPV-negative tumors showed a mutational spectrum concordant with published lung squamous cell carcinoma analyses with enrichment for mutations in TP53, CDKN2A, MLL2, CUL3, NSD1, PIK3CA, and NOTCH genes. HPV-positive tumors showed unique mutations in DDX3X, FGFR2/3 and aberrations in PIK3CA, KRAS, MLL2/3, and NOTCH1 were enriched in HPV-positive tumors. Currently targetable genomic alterations were identified in FGFR1, DDR2, EGFR, FGFR2/3, EPHA2, and PIK3CA. EGFR, CCND1, and FGFR1 amplifications occurred in HPV-negative tumors, whereas 17.6% of HPV-positive tumors harbored mutations in fibroblast growth factor receptor genes (FGFR2/3), including six recurrent FGFR3 S249C mutations. HPV-positive tumors showed a 5.8% incidence of KRAS mutations, and DNA-repair gene aberrations, including 7.8% BRCA1/2 mutations, were identified. Conclusions: The mutational makeup of HPV-positive and HPV-negative HNSCC differs significantly, including targetable genes. HNSCC harbors multiple therapeutically important genetic aberrations, including frequent aberrations in the FGFR and PI3K pathway genes. Clin Cancer Res; 21(3); 632–41. ©2014 AACR. See related commentary by Krigsfeld and Chung, p. 495

1 January 2020 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
MSMyrick C. Shinall
Myrick C. Shinall
SAShipra Arya
Shipra Arya
AYAda Youk
Ada Youk
PVPatrick Varley
Patrick Varley
RSRupen Shah
Rupen Shah
DHDaniel E. Hall
Daniel E. Hall
Research shows that frailty among patients preoperatively is associated with postoperative outcomes.1-4 Patients who are frail have higher rates of morbidity, mortality, and failure to rescue after major procedures across surgical specialties.5-16 Patients who are frail also have higher rates of morbidity after ambulatory procedures typically considered to be minor.17 Thus, frailty is a salient, potentially modifiable patient characteristic in surgical practice.18-21

1 August 2016 in Journal of Surgical Research
Verified
Journal Article
Closed access
AFAbigail J. Fong
Abigail J. Fong
MSMeghan Smith
Meghan Smith
ALAlexander Langerman
Alexander Langerman

1 January 2020 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
AGAlexander Gelbard
Alexander Gelbard
CACatherine Anderson
Catherine Anderson
LBLynne D. Berry
Lynne D. Berry
MAMilan R. Amin
Milan R. Amin
MBMichael S. Benninger
Michael S. Benninger
DFDavid O. Francis
David O. Francis
The paradox of rare diseases is that any single diagnosis affects a small number of individuals, but 6% to 8% of the world population is afflicted.1 This fact renders rare diseases both difficult to study and a significant public health concern. Even basic epidemiologic studies of rare diseases are challenging given the heterogeneous, progressive clinical course of the rare disease and the geographic dispersion of patients.2 Geographic distribution requires an extensive recruitment and monitoring infrastructure, dramatically increasing the cost and time required for participant accrual. These barriers, coupled with small markets, reduce incentives for the pharmaceutical industry and funders to support rare disease research,3 constrain evidence, and result in clinical practice variation and inconsistent patient outcomes.

1 October 2014 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
ESEmily Walker Stockert
Emily Walker Stockert
ALAlexander Langerman
Alexander Langerman
Efficiency in the operating room has become a topic of great interest. This study aimed to quantify the percent use of instruments among common instrument trays across 4 busy surgical services: Otolaryngology, Plastic Surgery, Bariatric Surgery, and Neurosurgery. We further aimed to calculate the costs associated with tray and instrument sterilization, as well as the implications of missing or damaged instruments. This was a single-site, observational study conducted on the surgical instrumentation at a large academic medical center in Chicago. Data were collected through direct observation by a trained investigator. Operating room instrument use and labor time required for cleaning and repacking instrument trays in central sterile processing (CSP) were analyzed using descriptive statistics and linear regression. Institutional data on volume and expenses were gathered from hospital leadership. Forty-nine procedures and 237 individual trays were observed. Average instrument (±SD)use rates were 13.0% for Otolaryngology (±4.2%), 15.5% for Plastic Surgery (±2.9%), 18.2% for Bariatric Surgery (±5.0%), and 21.9% for Neurosurgery (±1.7%). An increasing number of instruments per tray was associated with decreased use and increased instrument error rate. Using recorded labor time, the cost of cleaning and repackaging an individual instrument was calculated to be $0.10. Adding in CSP operating expenses and instrument depreciation per use, total processing cost per instrument increases to $0.51 or more. Our study demonstrates that the percent use of instruments across surgical specialties and multiple tray types is low. Attention to tray composition may result in immediate and significant cost savings.

1 April 2012 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
SASanjay M. Athavale
Sanjay M. Athavale
ALAlexander Langerman
Alexander Langerman
SRSanjeet V. Rangarajan
Sanjeet V. Rangarajan
RSRobert J. Sinard
Robert J. Sinard
JNJames L. Netterville
James L. Netterville
Research from JAMA Otolaryngology–Head & Neck Surgery — Natural History of Cervical Paragangliomas — Outcomes of Observation of 43 Patients